Lymphoma patients get continued access to experimental drug in Long-Term safety study
NCT ID NCT05688475
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study offers ongoing treatment with the drug CC-122 (Avadomide) to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor long-term safety and serious side effects. Participants may also receive dexamethasone alongside CC-122.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 100
New York, New York, 10065, United States
-
Local Institution - 101
Nashville, Tennessee, 37203, United States
-
Local Institution - 102
Madison, Wisconsin, 53792, United States
-
Local Institution - 300
Bordeaux, 33076, France
-
Local Institution - 301
Marseille, 13273, France
-
Local Institution - 400
Amsterdam, 1105, Netherlands
-
Local Institution - 500
Koto-ku, Tokyo, 1358550, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CC-122 (Avadomide) with or without dexamethasone
What this could lead to
If successful, this could show that long-term CC-122 treatment is safe and helps control Non-Hodgkin Lymphoma over many years.
What could go wrong
This is a small, early-phase extension study with only 12 participants, so results may not apply broadly. Long-term side effects remain possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.